SkinKandy
Thesis
SkinKandy is building a genuine competitive position: an in-house piercer training pipeline that takes competitors an estimated 18-24 months to replicate, 89% gross margins, and a 22% return on invested capital funded entirely from operating cash flow. That is a quality business by most conventional measures. The open question is what the current share price of $2.50 already assumes about how long that position holds and how far the store rollout has to run.
The Business
SkinKandy operates 109 specialty piercing stores across Australia and New Zealand, formalising a category historically served by unregulated kiosks and tattoo parlours. The model is services-led rather than product-led: 90% of piercings use needle technique rather than gun piercing, supporting premium pricing and a loyal customer base of 1.1 million KandyClub members. Roughly half of revenue is repeat service rather than one-off product sales. The company is expanding into South Africa in the second half of FY27, its first international test.
Recent Performance
SkinKandy listed in May 2026 and has traded for roughly three months. In its maiden result as a public company, revenue rose 29% to $90.2 million (FY25: $70.1 million) and beat prospectus forecasts on revenue, EBITDA and net profit. Like-for-like sales growth (revenue from stores open more than a year) ran at 9.6% through a period of elevated interest rates, an unusually resilient result for consumer discretionary retail.
Outlook
Revenue growth is expected to decelerate over the next few years as the 109-store base matures and like-for-like growth fades from 9.6% toward a more sustainable mid-single-digit rate. EBITDA margin is expected to expand over the same period, driven mechanically by store maturation: 54% of the current store fleet is under 36 months old and still climbing toward peak productivity. Management has flagged dividends beginning in FY29, funded from a minority of free cash flow, with the remainder reinvested into continued store rollout.
Our Valuation
Our valuation work combines a discounted cash flow analysis with trading multiples against listed specialty retail peers. The two methods converge closely, which gives us confidence in the reasonableness of the inputs, but the current price requires several favourable assumptions to hold simultaneously, most notably that the 9.6% like-for-like growth rate reflects structural demand rather than a fading post-pandemic effect. The full scenario analysis, including bear and bull case outcomes and our probability weightings, is available to subscribers.
Key Risks
The 9.6% like-for-like growth rate has only three years of supporting history and could fade toward a low single-digit rate faster than the market currently assumes, which would stall the operating leverage the margin expansion thesis depends on. A funded competitor entering the category, whether an existing jewellery retailer or a private equity-backed entrant, could compress margins and shorten the window of uncontested growth that currently protects SkinKandy's economics. A broader consumer discretionary downturn, with the cash rate at cycle highs and unemployment rising, poses a further risk to a demand pattern that has not yet been tested through a genuine downturn.
What to Watch
The thesis-defining event is the half-year result in February 2027, which will confirm whether like-for-like growth is structural or a fading post-pandemic trend.
- February 2027 1H FY27 results — like-for-like growth holding near current levels would support the structural growth case; a marked slowdown would signal a faster fade than modelled.
- ~March 2027 Whiteoak private equity escrow expiry — a roughly 35% stake becomes tradeable, creating potential technical selling pressure independent of fundamentals.
Business
Company Description
SkinKandy runs 109 specialty piercing stores across Australia and New Zealand, predominantly in shopping centres. The core offering is needle-based ear and body piercing alongside jewellery sales, with services generating roughly half of revenue and product sales the balance. The company operates an in-house piercer certification programme rather than relying on external training, giving it direct control over service quality and store rollout speed. A first international store is planned for South Africa in the second half of FY27, testing whether the model travels beyond its home market.
Where the Growth Is
Store rollout is the primary growth engine, contributing roughly 60% of revenue growth, with like-for-like sales growth contributing the remaining 40%. The store network is expected to grow from 109 to more than 175 over the next several years, with new store openings tapering from 18-22 per year currently to 1-2 per year as the network matures. The durability of like-for-like growth through this rollout window is the single biggest swing factor in how the market ultimately prices the business.
Competitive Position
SkinKandy's principal advantage is its training infrastructure: 770 SK Certified piercers, growing 22% year on year, built through a proprietary certification programme rather than hired from a competitive labour pool. Replicating this pipeline requires an estimated 18-24 months for any new entrant, which is currently the binding constraint on competition. No scaled competitor exists in the formalised ANZ piercing category today, and the competitive position appears to be widening rather than narrowing as the store network grows. We estimate this advantage holds for five to seven years before category maturity or a well-funded entrant erodes it.
Management & Capital Discipline
Management has funded store rollout entirely from operating cash flow, spending approximately $340,000 per new store while maintaining a net cash balance sheet throughout the growth phase. There has been no debt-funded expansion and no value-destructive acquisitions. The maiden result as a listed company beat prospectus forecasts on revenue, EBITDA, and net profit. The honest caveat: SkinKandy operates a single-founder leadership model, and the business has no visible succession plan, a key-person risk that a longer operating history has not yet tested.
Financial Position
SkinKandy holds net cash of $13.8 million with no interest-bearing debt and an undrawn $2.5 million facility. Capital expenditure of $7.4 million in FY26 was funded entirely from the $21.3 million of operating cash flow generated in the same period. The balance sheet carries no refinancing risk and provides ample flexibility to fund the South Africa expansion without raising equity. This is a business that could weather a consumer downturn without financial distress.
Read the full report
Our complete analysis of SkinKandy includes: